Physician profile
Danielle Taylor
NPI 1386901288
$9,853.64
in general payments reported to CMS, 2019-2025
24 companies · $1,638 in 2025
The $1,638 reported for 2025 was more than what 80% of Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $2,310 · 2021: $1,327 · 2022: $1,665 · 2023: $1,309 · 2024: $1,478 · 2025: $1,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,689 · Travel and Lodging: $421 · Consulting Fee: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,689.48 |
| Travel and Lodging | $420.99 |
| Consulting Fee | $315.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,538.89 | 2021-2025 | Interstim, Nuro |
| Coloplast Corp | $1,738.04 | 2020-2025 | Altis, Speedicath |
| Medtronic USA, INC. | $931.32 | 2020 | |
| Boston Scientific Corporation | $368.72 | 2019-2025 | Solyx Sis System |
| Astellas Pharma US INC | $326.21 | 2023-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $263.18 | 2019-2021 | |
| Axonics, INC. | $176.16 | 2020-2024 | Axonics |
| Abbvie INC. | $120.20 | 2022-2025 | Botox |
| Caldera Medical, INC | $62.42 | 2023 | Desara |
| Urovant Sciences INC | $55.45 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $43.10 | 2023 | Gemtesa |
| Rochester Medical Corporation | $32.24 | 2019-2020 | |
| Olympus America INC. | $27.73 | 2023-2024 | Itind System |
| Ambu INC. | $23.79 | 2022 | |
| Ethicon US, LLC | $18.18 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $16.75 | 2023 | |
| Amag Pharmaceuticals, INC. | $16.34 | 2020 | |
| Myovant Sciences INC. | $15.66 | 2021 | |
| Virtus Pharmaceuticals LLC | $15.07 | 2020 | |
| Pfizer INC. | $14.85 | 2020 | |
| Array Biopharma INC | $14.62 | 2024 | Xalkori, Lorbrena, Braftovi |
| Cook Medical LLC | $14.39 | 2021 | |
| Coopersurgical, INC. | $14.02 | 2021 | |
| Travere Therapeutics, INC. | $6.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.